The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Reflecting on progress in MPN research and care: a lifetime perspective
Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, comments on receiving the Lifetime Achievement Award and highlights the significant advances made in the field of myeloproliferative neoplasms (MPNs), including key discoveries such as driver mutations and targeted therapies, and the shift towards disease modification. Prof. Harrison notes that this progress is a testament to collaborative efforts within the field. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, it was a great honour, of course, and an absolutely overwhelming honour to receive the Lifetime Achievement Award. And my first thought was, well, I’m not old enough to get that. But I think there have been so many advances in this field, and that’s also marked by the wonderful award of the Ernest Beutler Prize to Radek Skoda and Ruben Mesa at ASH also this year. So I think it’s really about the MPN field...
Well, it was a great honour, of course, and an absolutely overwhelming honour to receive the Lifetime Achievement Award. And my first thought was, well, I’m not old enough to get that. But I think there have been so many advances in this field, and that’s also marked by the wonderful award of the Ernest Beutler Prize to Radek Skoda and Ruben Mesa at ASH also this year. So I think it’s really about the MPN field. And I would say that although it’s a personal lifetime achievement award, really it’s a team MPN award. So well done and a big clap to everyone in the field. And that’s also about the key discoveries that we’ve had in the last 20 years: driver mutations closely followed by mutation-targeted or at least pathway-targeted therapies and then moving now towards the era of disease modification marked at EHA for example by calreticulin data, also the data from the SENTRY study. And we’ll also see the data with AJAX, a more specific JAK inhibitor, which I think is super exciting and very important for patients. I think the field has also progressed a lot through several key facets. One, it is the most incredibly collaborative, friendly field. And you achieve things much more in collaboration. Everything is a team effort. And that includes collaboration between clinicians, scientists, pharma, but also really importantly, patients. And our field has incredibly strong patient advocates who work tirelessly with clinicians and with the rest of the community to make sure the patient voice is heard. So a massive call out to everybody and huge acknowledgement to them.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
